Immunotherapy
Food allergies, education take spotlight at ACAAI Annual Scientific Meeting
After working with the American College of Asthma, Allergy & Immunology for 3 decades, Kathleen May, MD, FACAAI, is excited to be taking its reins as president during its 2022 Annual Scientific Meeting, Nov. 10 to 14, in Louisville, Ky.
Immunotherapy combination shrinks tumors in surgery-ineligible renal cell carcinoma
Most patients with renal cell carcinoma ineligible for surgery and ablation achieved tumor reduction after treatment with nivolumab plus ipilimumab, according to study results.
Parker Institute adds Dana-Farber, Gladstone Institutes to cancer research collaboration
Parker Institute for Cancer Immunotherapy added Dana-Farber Cancer Institute and Gladstone Institutes to its immuno-oncology research partnership network.
FDA grants priority review to lanadelumab-flyo for pediatric hereditary angioedema attacks
The FDA has granted priority review to a supplemental biologics license application for the potential expanded use of lanadelumab-flyo to prevent hereditary angioedema attacks in patients aged 2 to younger than 12 years.
Alzamend submits IND application for Alzheimer’s vaccine trial
Alzamend Neuro has submitted an investigational new drug application to the FDA for its Alzheimer’s immunotherapeutic product, ALZN002, according to a company press release.
Subcutaneous immunotherapy not linked to severe reactions in severe asthma
Patients with severe asthma who are on subcutaneous immunotherapy for allergy treatment do not experience an increased risk for moderate to severe systemic reactions, according to a study published in Annals of Allergy, Asthma & Immunology.
Novel test may predict adverse events with, recurrence after immunotherapy
An experimental test may help predict which patients with cancer may develop disease recurrence after immunotherapy treatment, according to study results published in Clinical Cancer Research.
Short-course neoadjuvant immunotherapy confers high response rates in colon cancer subset
Two cycles of neoadjuvant nivolumab plus low-dose ipilimumab induced durable pathologic responses among patients with mismatch repair-deficient colon cancer, according to study results presented at ESMO Congress.
Timing of pembrolizumab makes a difference in resectable melanoma
Neoadjuvant pembrolizumab extended event-free survival compared with adjuvant-only administration of the anti-PD-1 therapy among patients with resectable melanoma, according to phase 2 study results presented at ESMO Congress.
Q&A: Inaugural North American conference to focus on pediatric food allergy
As pediatric allergy rates increase and therapy progresses, experts will address these issues at the inaugural North American Pediatric Allergy & Asthma Congress, Sept. 21 to 22, in Quebec City.